Adrenomed will co-host the symposium “Beyond Standard of Care – New Perspectives on Vascular Integrity in Shock” on September 13th, 12:00-13:30 CET. Chair: Prof. Dr. med. Frank M. Brunkhorst, Head of the Center for Clinical
April 2019 by Cormac Sheridan, Staff Writer.
BIO-Europe Spring 2019: Adrenomed’s Hein on sepsis and beyond. “We don’t want sepsis to be the number one killer in the USA’s ICU anymore. We want to substantially cut the mortality rate” said Adrenomed CBO
Hennigsdorf (Germany), May 6, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at
BIO International Convention 3-6 June | Philadelphia, PA, USA Link to the Conference
20th Annual Bio€quity Europe 20-21 May | Crowne Plaza Barcelona Fira Center, Barcelona, Spain Company Presentation on the 20th of May, 16:30 CET, Room Rossini 2 Speaker: Dr. Frauke Hein, Chief Business Officer Link to
Swiss Biotech Day 2019 and Annual General Assembly of the Swiss Biotech Association 7 May | Congress Center, Basel, Switzerland Link to the Conference
BIO-Europe Spring 25–27 March 2019 | Messe Wien Exhibition and Congress Center, Vienna, Austria Company Presentation on the 27th of March, 9:30 AM CET, Room Schubert 5 (on Level 1). Category: Cardiovascular. Speaker: Dr. Frauke
ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19-22, 2019 | Brussels, Belgium Talk: March 21, 2019, at 8:30 – 8:45 AM CET, Salle M (Bozar) “The adrenomedullin antibody adrecizumab” during the
AdrenOSS-II trial continues as planned after positive interim efficacy analysis triggered by the treatment of 50% of randomized patients Proof-of-concept trial design testing Adrecizumab in early septic shock presented at International Symposium on Intensive Care
By loading the map, you agree to Google's privacy policy.
Learn more
© 2024 AdrenoMed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung | Expanded Access Policy
